<DOC>
	<DOC>NCT00690105</DOC>
	<brief_summary>Patients with facial atopic eczema and a poor response to topical corticosteroid applied either Protopic or Fluticasone ointment twice a day for 3 weeks. They could continue during 3 more weeks once a day if needed or change for the other ointment.</brief_summary>
	<brief_title>Protopic Ointment in Adult Atopic Eczema of the Face</brief_title>
	<detailed_description>Treatments were to be applied twice daily over all lesions on the face (except for the eyelids) until clearance, for a maximum of 3 weeks and then, in case of uncleared residual lesions, once daily for up to 3 further weeks. In the event of a flare-up the treatment was to be resumed twice a day until the end of the study.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Moderate to severe AD (Rajka &amp; Langeland score) with lesions to the head and neck defined as 'red face' or 'facial eczema': erythema affecting at least 10% of the surface of the 'face' (head, neck, chest, nape of neck), due to longterm AD At least two flareups of 'facial' eczema during the 12 months prior to inclusion and, in the investigator's opinion, conventional treatment had proved ineffective or poorly tolerated Female patients of childbearing age: effective means of contraception throughout the period of the study and for four weeks following the end of the study Informed consent Therapeutic washout for atopic dermatitis treatments Genetic epidermal barrier defect, such as Netherton's syndrome, or suffering from erythroderma Seborrheic dermatitis or contact dermatitis affecting the 'face', or any other facial erythema of nonatopic origin Clinical infection due to the VZV virus (varicella, zona), HSV12 viruses (herpes), verruca vulgaris or molluscum contagiosum Superinfected eczema Known hypersensitivity to macrolides or to any other excipient in tacrolimus 0.1% ointment Known hypersensitivity to one of the agents contained in the fluticasone 0.005% ointment preparation Ulcerated lesions, of whatever type Moderate to severe acne or rosacea Patients who participated at the same time in another clinical study or who had participated in another clinical study within 28 days prior to inclusion in the study Any type of substance abuse (including that of drugs and alcohol) or any mental disorder/psychological state which, in the investigator's opinion, might interfere with the patient's followup Serologicallyproven HIV positivity</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Dermatitis, Atopic</keyword>
	<keyword>Dermatologic Agents</keyword>
	<keyword>Topical Drug Administration</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Calcineurin</keyword>
	<keyword>Corticosteroid</keyword>
	<keyword>Fluticasone propionate</keyword>
	<keyword>Face</keyword>
</DOC>